Growth Metrics

Eli Lilly (LLY) Liabilities and Shareholders Equity (2016 - 2025)

Eli Lilly (LLY) has disclosed Liabilities and Shareholders Equity for 17 consecutive years, with $112.5 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 42.89% year-over-year to $112.5 billion, compared with a TTM value of $417.7 billion through Dec 2025, up 43.97%, and an annual FY2025 reading of $112.5 billion, up 42.89% over the prior year.
  • Liabilities and Shareholders Equity was $112.5 billion for Q4 2025 at Eli Lilly, down from $114.9 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $114.9 billion in Q3 2025 and bottomed at $46.8 billion in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $66.0 billion, with a median of $56.4 billion recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity fell 1.56% in 2022, then surged 52.02% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $48.8 billion in 2021, then grew by 1.4% to $49.5 billion in 2022, then rose by 29.33% to $64.0 billion in 2023, then rose by 22.98% to $78.7 billion in 2024, then soared by 42.89% to $112.5 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for LLY at $112.5 billion in Q4 2025, $114.9 billion in Q3 2025, and $100.9 billion in Q2 2025.